🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07406308
Starting soon Phase EARLY_PHASE1

A Comparative Analysis of Mid- to Long-Term Outcomes: Paclitaxel-Coated Balloon With Debulking Versus Paclitaxel-Coated Balloon Alone in the Treatment of Chronic Femoropopliteal Artery Occlusions

NCT07406308 · tracked via the Priya Life Science China tracker
Sponsor
Peking Union Medical College Hospital
Phase
Phase EARLY_PHASE1
Started
2026-04-20
Last updated
2026-02-12

Condition(s) studied

Femoropopliteal Artery Occlusion

Investigational drug(s) / intervention(s)

paclitaxel-coated balloon angioplastypaclitaxel-coated balloon angioplasty with debulking procedures

paclitaxel-coated balloon angioplasty: No debulking procedures were taken

paclitaxel-coated balloon angioplasty with debulking procedures: The patient underwent DCB treatment along with debulking procedures (such as laser or plaque rotational atherectomy, etc.).

Study summary

This study aims to compare mid-to long-term outcomes of paclitaxel-coated balloon angioplasty with adjunctive debulking versus paclitaxel-coated balloon angioplasty alone for the treatment of chronic femoropopliteal artery diseases.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Subject age 18-85yrs. * Subject has been informed of the nature of the study, agrees to participate, and has signed a Medical Ethics Committee approved consent form. * Subject understands the duration of the study, agrees to attend follow-up visits, and agrees to complete the required testing. * Rutherford category 2-5. * Subject has atherosclerotic de novo, non-stented restenotic, or in-stent restenotic/occlusive lesions in the superficial femoral artery (SFA) and/or popliteal artery (P1 segment). * Patent inflow artery with stenosis \<30% by visual estimation (or by core lab assessment if available) and at least 1 infrapopliteal artery to the ankle (\<50% diameter stenosis). * A guidewire has successfully traversed the target treatment segment. Exclusion Criteria: * Subject presents with acute arterial embolism or thrombosis requiring thrombectomy or thrombolysis for limb ischemia. * Subject has arterial occlusion caused by thromboangiitis obliterans (Buerger's disease) or other forms of immune-mediated vasculitis. * Subject has undergone surgery on the target vessel within the past 3 months, or has experienced repeated failures of endovascular therapy and is deemed unsuitable for further endovascular intervention. * Subject has an uncontrolled thrombophilia or hypercoagulable state. * Subject has a severe systemic disease (e.g., malignancy) with a life expectancy of less than 1 year. * Subject has contraindications or intolerance to antiplatelet/anticoagulant medications, such as aspirin, clopidogrel, or heparin. * Subject is pregnant or breastfeeding. * Subject meets one or more of the following conditions: chronic renal insufficiency (SCr ≥ 2.5 mg/dL) or on regular dialysis; cardiovascular or cerebrovascular surgery within the past 1 month; or severe sequelae from a major stroke. * Subject has a known allergy to nitinol alloy, paclitaxel, or contrast agents.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking Union Medical College Hospital Beijing China

More Peking Union Medical College Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07406308 on ClinicalTrials.gov ↗ ← All trials in China